PHATHOM PHARMACEUTICALS, INC. (PHAT) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 164.59M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 327.07M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $0.00 | $164.59M | (m) | (m) | $327.07M | (m) |
| 2026-03-31 | (m) | (m) | $0.00 | $163.68M | (m) | (m) | $305.12M | (m) |
| 2025-12-31 | (m) | (m) | $0.00 | $209.09M | (m) | (m) | $259.15M | (m) |
| 2025-09-30 | (m) | (m) | $0.00 | $207.09M | (m) | (m) | $240.29M | (m) |
| 2025-06-30 | (m) | (m) | $0.00 | $205.14M | (m) | (m) | $250.22M | (m) |
| 2025-03-31 | (m) | (m) | $0.00 | $203.25M | (m) | (m) | $294.21M | (m) |
| 2024-12-31 | (m) | (m) | $0.00 | $201.41M | (m) | (m) | $378.32M | (m) |
| 2024-09-30 | (m) | (m) | $0.00 | $175.73M | (m) | (m) | $387.04M | (m) |
| 2024-06-30 | (m) | (m) | $0.00 | $174.42M | (m) | (m) | $319.38M | (m) |
| 2024-03-31 | (m) | (m) | $0.00 | $149.02M | (m) | (m) | $356.50M | (m) |
| 2023-12-31 | (m) | (m) | $0.00 | $137.84M | (m) | (m) | $413.84M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $99.26M | (m) | (m) | $236.99M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $97.81M | (m) | (m) | $265.04M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $96.64M | (m) | (m) | $144.01M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $95.26M | (m) | (m) | $164.81M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $93.88M | (m) | (m) | $201.93M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $92.43M | (m) | (m) | $213.50M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $91.04M | (m) | (m) | $149.05M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $89.67M | (m) | (m) | $189.43M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $88.31M | (m) | (m) | $228.38M | (m) |
| 2021-06-30 | (m) | (m) | $10.35M | $37.34M | (m) | (m) | $214.58M | (m) |
| 2021-03-31 | (m) | (m) | $11.77M | $35.59M | (m) | (m) | $246.36M | (m) |
| 2020-12-31 | (m) | (m) | $7.35M | $39.63M | (m) | (m) | $295.11M | (m) |
| 2020-09-30 | (m) | (m) | $5.56M | $41.06M | (m) | (m) | $230.89M | (m) |
| 2020-06-30 | (m) | (m) | $1.39M | $44.87M | (m) | (m) | $252.42M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $22.78M | (m) | (m) | $257.18M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |